Liu Mei, Wang Rui-Bo, Xing Jian-Hong, Tang Ying-Xue
Chinese Medicine College, Shandong University of Traditional Chinese Medicine, Jinan, 250355, Shandong, People's Republic of China.
Department of Obstetrics, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250011, Shandong, People's Republic of China.
Int J Gen Med. 2021 Jun 3;14:2313-2320. doi: 10.2147/IJGM.S297344. eCollection 2021.
Preeclampsia (PE), a serious pregnancy disorder, is responsible for maternal and fetal mortality worldwide. At present, numerous candidate biomarkers have been studied to predict PE.
To explore the role of Corin in PE risk prediction and then evaluate the predictive ability of soluble vascular endothelial growth factor receptor-1 (sFlt-1), placenta growth factor (PLGF), and sFlt-1/PLGF after the addition of Corin.
A total of 135 pregnant women from Affiliated Hospital of Shandong University of Traditional Chinese Medicine participated in this study in their first trimester. A nested case-control study was conducted and all subjects were divided into PE groups (n=46) and controls (n=89). The levels of PLGF, sFlt-1, sFlt-1/PLGF ratio, and Corin of the two groups at 12-16 weeks of gestation were measured and analyzed. Receiver operating characteristic (ROC) curve, net reclassification index (NRI) and integrated discrimination index (IDI) were calculated to evaluate the predictive ability of various biomarkers.
The concentrations of sFlt-1, sFlt-1/PLGF, and Corin in PE group were significantly higher than that in controls, while the concentration of PLGF in the PE group was lower. The area under curve (AUC) of sFlt-1, PLGF and sFlt-1/PLGF for predicting PE was 0.786, 0.719 and 0.866, respectively. Combined with Corin, the prediction ability of the above biomarkers could be improved to 0.876, 0.847, and 0.897, respectively. Corin in combination with sFlt-1/PLGF resulted in improvements with 12.6% being reclassified and a resulting NRI of 0.142 (0.0200.263) and IDI of 0.087 (0.0370.137).
The addition of Corin to sFlt-1, PLGF and sFlt-1/PLGF can improve the ability of each marker to predict PE risk. Corin in combination with sFlt-1/PLGF can be used as ideal markers to identify the pregnant women who subsequently develop PE, which will help in risk stratification and better therapeutic management.
子痫前期（PE）是一种严重的妊娠疾病，在全球范围内导致母婴死亡。目前，已对众多候选生物标志物进行了研究以预测PE。
探讨Corin在PE风险预测中的作用，并评估添加Corin后可溶性血管内皮生长因子受体-1（sFlt-1）、胎盘生长因子（PLGF）和sFlt-1/PLGF的预测能力。
山东大学附属中医医院的135名孕妇在孕早期参与了本研究。进行了一项巢式病例对照研究，所有受试者被分为PE组（n = 46）和对照组（n = 89）。测量并分析了两组在妊娠12 - 16周时PLGF、sFlt-1、sFlt-1/PLGF比值和Corin的水平。计算受试者工作特征（ROC）曲线、净重新分类指数（NRI）和综合判别指数（IDI）以评估各种生物标志物的预测能力。
PE组中sFlt-1、sFlt-1/PLGF和Corin的浓度显著高于对照组，而PE组中PLGF的浓度较低。sFlt-1、PLGF和sFlt-1/PLGF预测PE的曲线下面积（AUC）分别为0.786、0.719和0.866。与Corin联合使用时，上述生物标志物的预测能力可分别提高到0.876、0.847和0.897。Corin与sFlt-1/PLGF联合使用导致12.6%的重新分类改善，净重新分类指数（NRI）为0.142（0.0200.263），综合判别指数（IDI）为0.087（0.0370.137）。
在sFlt-1、PLGF和sFlt-1/PLGF中添加Corin可提高各标志物预测PE风险的能力。Corin与sFlt-1/PLGF联合可作为识别随后发生PE的孕妇的理想标志物，这将有助于风险分层和更好的治疗管理。
